Gaut D, et al. - In order to clearly explain patient and disease features that can predict outcome after high-dose chemotherapy followed by autologous stem cell transplantation (HDC/ASCT) in DLBCL, researchers performed this retrospective analysis of 111 DLBCL patients (78 relapsed, 33 refractory) who had received HDC/ASCT at their institution from 2010-2015. Participants were observed for a median duration of 4.6 years, after which, the probability of 5-year progression-free survival (PFS) and 5-year overall survival (OS) was estimated to be 62.2% and 68.9%, respectively. A lower probability of PFS and OS was noted only in relation to more than 3 chemotherapy regimens before ASCT. Lower chance of PFS was also observed in relation to male gender and high International Prognostic Index (IPI) score at time of ASCT. The outcome post-ASCT was not predicted by NCCN IPI and age-adjusted IPI at time of ASCT. Following ASCT, similar outcomes were observed in patients with refractory and relapsed disease.